Crispr, Vertex shares fall after FDA halts sickle-cell disease trial
and Vertex Pharmaceuticals Inc.
said late Wednesday the U.S. Food and Drug Administration has put a hold on a new-drug application for a drug used for the treatment of sickle-cell disease, "pending the resolution of certain questions that will be provided by the FDA as part of its review." The application was filed in April ahead of trials in adult patients, they said. The companies said they expect "additional information" from the FDA shortly and plan to work with the agency "toward a resolution." Shares of Crispr fell more than 18% in late trading after ending the regular session 6.8% higher. Vertex shares were off 2.3% after a 0.9% advance on Wednesday.
Published at Wed, 30 May 2018 21:02:00 +0000